Alps Advisors Inc Hille Vax, Inc. Transaction History

Alps Advisors Inc

$14.5 Billion
Q2 2024

A detailed history of Alps Advisors Inc transactions in Hille Vax, Inc. stock. As of the latest transaction made, Alps Advisors Inc holds 38,787 shares of HLVX stock, worth $68,265. This represents 0.0% of its overall portfolio holdings.

Number of Shares

38,787

Holding current value

$68,265

% of portfolio

0.0%

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$11.86 - $15.93 $460,013 - $617,876	38,787 New	38,787 $560,000
Q3 2023 Nov 14, 2023	BUY	$11.59 - $16.7 $1,182 - $1,703	102 Added 0.35%	28,914 $388,000
Q2 2023 Aug 14, 2023	BUY	$12.93 - $18.76 $88,428 - $128,299	6,839 Added 31.12%	28,812 $495,000
Q1 2023 May 10, 2023	SELL	$14.73 - $18.18 $9,441 - $11,653	-641 Reduced 2.83%	21,973 $363,000
Q4 2022 Feb 14, 2023	BUY	$13.52 - $21.46 $58,365 - $92,642	4,317 Added 23.59%	22,614 $378,000
Q3 2022 Nov 14, 2022	SELL	$10.5 - $22.01 $16,044 - $33,631	-1,528 Reduced 7.71%	18,297 $313,000
Q2 2022 Aug 11, 2022	BUY	$8.7 - $20.18 $172,477 - $400,068	19,825 New	19,825 $217,000

Others Institutions Holding HLVX

# of Institutions

Shares Held

40.5M

Call Options Held

Put Options Held

Frazier Life Sciences Management, L.P. Menlo Park, CA

10.6M
Shares

$18.7 Million
9.05% of portfolio
Deerfield Management Company, L.P. (Series C) New York, NY

4M
Shares

$7.05 Million
1.22% of portfolio
T. Rowe Price Investment Management, Inc. Baltimore, MD

3.48M
Shares

$6.13 Million
0.03% of portfolio
Black Rock Inc. New York, NY

2.09M
Shares

$3.68 Million
0.0% of portfolio
Franklin Resources Inc San Mateo, CA

1.99M
Shares

$3.5 Million
0.01% of portfolio

View Full List

About HilleVax, Inc.

Ticker HLVX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 33,427,200
Market Cap $58.8M
Description
HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. It is developing HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company is headquartered in Boston, Massachusetts.

More about HLVX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Alps Advisors Inc, based on Form 13F filings with the SEC.

News

Stay updated on Alps Advisors Inc with notifications on news.

Account